Shilpa Medicare Limited Market Cap ($1.97 Billion)
Market Cap & Net Worth: Shilpa Medicare Limited (SHILPAMED)
Shilpa Medicare Limited market cap. Shilpa Medicare Limited (NSE:SHILPAMED) has a market capitalization of $1.97 Billion (Rs182.11 Billion) as of November 5, 2026. Listed on the NSE stock exchange, this India-based company holds position #6023 globally and #274 in its home market, demonstrating a 2.92% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Shilpa Medicare Limited's stock price Rs931.10 by its total outstanding shares 195581816 (195.58 Million). Also see how efficiently does Shilpa Medicare Limited generate cash for how efficiently the company converts equity into cash flow.
Shilpa Medicare Limited Market Cap History (2015–2026)
Shilpa Medicare Limited market cap history from 2015 to 2026. Data shows growth from $1.04 Billion to $1.97 Billion (6.32% CAGR). Check SHILPAMED live share price for real-time trading data and today's change.
Index Memberships
Shilpa Medicare Limited is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NIFTY MICROCAP 250
NIFTYMICROCAP250
|
$145.41 Billion | 1.35% | #10 of 250 |
|
NIFTY TOTAL MARKET
NIFTYTOTALMKT
|
$3.14 Trillion | 0.06% | #238 of 750 |
Weight: Shilpa Medicare Limited's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Shilpa Medicare Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Shilpa Medicare Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore SHILPAMED year-over-year net asset growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.05x
Shilpa Medicare Limited's market cap is 0.05 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.87x
Shilpa Medicare Limited's market cap is 0.87 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.44 Billion | $6.38 Billion | $1.08 Billion | 0.23x | 1.33x |
| 2017 | $1.29 Billion | $7.30 Billion | $1.08 Billion | 0.18x | 1.20x |
| 2018 | $806.26 Million | $7.49 Billion | $1.05 Billion | 0.11x | 0.77x |
| 2019 | $592.10 Million | $7.01 Billion | $1.12 Billion | 0.08x | 0.53x |
| 2020 | $947.93 Million | $8.99 Billion | $1.56 Billion | 0.11x | 0.61x |
| 2021 | $1.13 Billion | $9.00 Billion | $1.48 Billion | 0.13x | 0.76x |
| 2022 | $588.75 Million | $11.40 Billion | $606.62 Million | 0.05x | 0.97x |
| 2023 | $698.63 Million | $10.43 Billion | -$325.33 Million | 0.07x | N/A |
| 2024 | $1.72 Billion | $11.53 Billion | $318.74 Million | 0.15x | 5.41x |
| 2025 | $679.28 Million | $12.86 Billion | $782.93 Million | 0.05x | 0.87x |
Competitor Companies of SHILPAMED by Market Capitalization
Companies near Shilpa Medicare Limited in the global market cap rankings as of November 5, 2026. Also see SHILPAMED current and non-current assets for a full breakdown of the balance sheet.
Key companies related to Shilpa Medicare Limited by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #514 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #538 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #588 globally with a market cap of $45.79 Billion USD ( CN¥312.89 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #621 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #514 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #538 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $47.80 |
| #588 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.79 Billion | CN¥49.05 |
| #621 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.50 |
Market Capitalization of Shilpa Medicare Limited (2015–2026)
Market capitalization of Shilpa Medicare Limited from 2015 to today. Between 2015 and today, Shilpa Medicare Limited's market cap moved from $1.04 Billion to $ 1.97 Billion, with a yearly change of 6.32%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Rs1.97 Billion | +189.93% |
| 2025 | Rs679.28 Million | -60.62% |
| 2024 | Rs1.72 Billion | +146.90% |
| 2023 | Rs698.63 Million | +18.66% |
| 2022 | Rs588.75 Million | -47.83% |
| 2021 | Rs1.13 Billion | +19.06% |
| 2020 | Rs947.93 Million | +60.10% |
| 2019 | Rs592.10 Million | -26.56% |
| 2018 | Rs806.26 Million | -37.62% |
| 2017 | Rs1.29 Billion | -10.31% |
| 2016 | Rs1.44 Billion | +38.89% |
| 2015 | Rs1.04 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of Shilpa Medicare Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.97 Billion USD |
| MoneyControl | $1.97 Billion USD |
| MarketWatch | $1.97 Billion USD |
| marketcap.company | $1.97 Billion USD |
| Reuters | $1.97 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Shilpa Medicare Limited
Shilpa Medicare Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, biosimilars, and contract development and manufacturing organisation in India, the United States, Europe, and internationally. The company offers various oncology and non-oncology APIs, such as anastrozole, acebrophylline, ambroxol hydrochloride, … Read more